PURPOSE: Apoptosis plays an important role in neoplastic processes. Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported. EXPERIMENTAL DESIGN: We investigated Bcl-B expression in normal human tissues and several types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating results with tumor stage, histologic grade, and patient survival. RESULTS: Bcl-B protein was strongly expressed in all normal plasma cells but found in only 18% of multiple myelomas (n = 133). Bcl-B immunostaining was also present in normal germinal center centroblasts and centrocytes and in approximately half of diffuse large B-cell lymphoma (n = 48) specimens, whereas follicular lymphomas (n = 57) did not contain Bcl-B. In breast (n = 119), prostate (n = 66), gastric (n = 180), and colorectal (n = 106) adenocarcinomas, as well as in non-small cell lung cancers (n = 82), tumor-specific overexpression of Bcl-B was observed. Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in breast cancer (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location (P = 0.02) of colorectal cancers, as well as with greater incidence of death from prostate cancer (P = 0.005) and shorter survival of patients with small cell lung cancer (P = 0.009). Conversely, although overexpressed in many gastric cancers, Bcl-B tended to correlate with better outcome (P = 0.01) and more differentiated tumor histology (P < 0.0001). CONCLUSIONS: Tumor-specific alterations in Bcl-B expression may define subsets of nonepithelial and epithelial neoplasms with distinct clinical behaviors.
PURPOSE: Apoptosis plays an important role in neoplastic processes. Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in humanmalignancies has not been reported. EXPERIMENTAL DESIGN: We investigated Bcl-B expression in normal human tissues and several types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating results with tumor stage, histologic grade, and patient survival. RESULTS:Bcl-B protein was strongly expressed in all normal plasma cells but found in only 18% of multiple myelomas (n = 133). Bcl-B immunostaining was also present in normal germinal center centroblasts and centrocytes and in approximately half of diffuse large B-cell lymphoma (n = 48) specimens, whereas follicular lymphomas (n = 57) did not contain Bcl-B. In breast (n = 119), prostate (n = 66), gastric (n = 180), and colorectal (n = 106) adenocarcinomas, as well as in non-small cell lung cancers (n = 82), tumor-specific overexpression of Bcl-B was observed. Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in breast cancer (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location (P = 0.02) of colorectal cancers, as well as with greater incidence of death from prostate cancer (P = 0.005) and shorter survival of patients with small cell lung cancer (P = 0.009). Conversely, although overexpressed in many gastric cancers, Bcl-B tended to correlate with better outcome (P = 0.01) and more differentiated tumor histology (P < 0.0001). CONCLUSIONS:Tumor-specific alterations in Bcl-B expression may define subsets of nonepithelial and epithelial neoplasms with distinct clinical behaviors.
Authors: N Inohara; T S Gourley; R Carrio; M Muñiz; J Merino; I Garcia; T Koseki; Y Hu; S Chen; G Núñez Journal: J Biol Chem Date: 1998-12-04 Impact factor: 5.157
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: S Krajewski; M Krajewska; L M Ellerby; K Welsh; Z Xie; Q L Deveraux; G S Salvesen; D E Bredesen; R E Rosenthal; G Fiskum; J C Reed Journal: Proc Natl Acad Sci U S A Date: 1999-05-11 Impact factor: 11.205
Authors: Cristina Correia; Sun-Hee Lee; X Wei Meng; Nicole D Vincelette; Katherine L B Knorr; Husheng Ding; Grzegorz S Nowakowski; Haiming Dai; Scott H Kaufmann Journal: Biochim Biophys Acta Date: 2015-03-27
Authors: Ramona F Curpan; Peter C Simons; Dayong Zhai; Susan M Young; Mark B Carter; Cristian G Bologa; Tudor I Oprea; Arnold C Satterthwait; John C Reed; Bruce S Edwards; Larry A Sklar Journal: Assay Drug Dev Technol Date: 2011-05-11 Impact factor: 1.738
Authors: Levi J Beverly; William W Lockwood; Parag P Shah; Hediye Erdjument-Bromage; Harold Varmus Journal: Proc Natl Acad Sci U S A Date: 2012-01-10 Impact factor: 11.205
Authors: Maryla Krajewska; Layton H Smith; Juan Rong; Xianshu Huang; Marc L Hyer; Nikolajs Zeps; Barry Iacopetta; Steven P Linke; Allen H Olson; John C Reed; Stan Krajewski Journal: J Histochem Cytochem Date: 2009-03-16 Impact factor: 2.479
Authors: Rafael Duran; Sahar Mirpour; Vasily Pekurovsky; Shanmugasundaram Ganapathy-Kanniappan; Cory F Brayton; Toby C Cornish; Boris Gorodetski; Juvenal Reyes; Julius Chapiro; Rüdiger E Schernthaner; Constantine Frangakis; MingDe Lin; Jessica D Sun; Charles P Hart; Jean-François Geschwind Journal: Clin Cancer Res Date: 2016-07-20 Impact factor: 12.531
Authors: Rachel Raab; Joseph A Sparano; Allyson J Ocean; Paul Christos; Mark Ramirez; Vincent Vinciguerra; Andreas Kaubisch Journal: Am J Clin Oncol Date: 2010-02 Impact factor: 2.339
Authors: Cody J Diehl; Grant D Barish; Michael Downes; Meng-Yun Chou; Sven Heinz; Christopher K Glass; Ronald M Evans; Joseph L Witztum Journal: Mol Endocrinol Date: 2011-01-27